CA2640997C - Doxorubicin formulations for anti-cancer use - Google Patents

Doxorubicin formulations for anti-cancer use Download PDF

Info

Publication number
CA2640997C
CA2640997C CA2640997A CA2640997A CA2640997C CA 2640997 C CA2640997 C CA 2640997C CA 2640997 A CA2640997 A CA 2640997A CA 2640997 A CA2640997 A CA 2640997A CA 2640997 C CA2640997 C CA 2640997C
Authority
CA
Canada
Prior art keywords
composition
weight
doxorubicin
copolymer
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2640997A
Other languages
English (en)
French (fr)
Other versions
CA2640997A1 (en
Inventor
Valery Alakhov
Evgueni Klinski
Kishore Patel
Grzegorz Pietrzynski
Original Assignee
Softkemo Pharma Corp
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Softkemo Pharma Corp, Supratek Pharma Inc filed Critical Softkemo Pharma Corp
Publication of CA2640997A1 publication Critical patent/CA2640997A1/en
Application granted granted Critical
Publication of CA2640997C publication Critical patent/CA2640997C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2640997A 2006-02-22 2007-02-08 Doxorubicin formulations for anti-cancer use Active CA2640997C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/359,352 US8148338B2 (en) 2006-02-22 2006-02-22 Doxorubicin formulations for anti-cancer use
US11/359,352 2006-02-22
PCT/CA2007/000182 WO2007095722A1 (en) 2006-02-22 2007-02-08 Doxorubicin formulations for anti-cancer use

Publications (2)

Publication Number Publication Date
CA2640997A1 CA2640997A1 (en) 2007-08-30
CA2640997C true CA2640997C (en) 2013-11-19

Family

ID=38428501

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2640997A Active CA2640997C (en) 2006-02-22 2007-02-08 Doxorubicin formulations for anti-cancer use

Country Status (7)

Country Link
US (1) US8148338B2 (https=)
EP (1) EP1991239B1 (https=)
JP (1) JP5449784B2 (https=)
KR (1) KR101074430B1 (https=)
CN (1) CN101389343B (https=)
CA (1) CA2640997C (https=)
WO (1) WO2007095722A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314151B2 (en) 2008-04-29 2012-11-20 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, and processes for using same
US8372888B2 (en) * 2008-04-29 2013-02-12 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, compositions and processes for using same
US20130150311A1 (en) * 2011-12-13 2013-06-13 Grzegorz Pietrzynski Mixed poloxamer excipients
US8912215B2 (en) * 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
EP2716291B1 (en) * 2012-10-08 2019-11-27 Universität Ulm Combination of opioids and anticancer drugs for cancer treatment
EP3068364B1 (en) * 2013-11-14 2021-11-03 Metro Biotech NSW Pty Ltd Nad+ precursor selected from nmn, naad, namn, or a pharmaceutically acceptable salt thereof, for use in treating a side effect of chemotherapy and/or radiotherapy in a subject
JP6875285B2 (ja) 2015-03-13 2021-05-19 コーニング インコーポレイテッド エッジ強度試験方法および装置
CA2984379C (en) 2015-04-28 2024-06-11 Newsouth Innovations Pty Limited Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies, and inactivity
WO2018237379A2 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8426672D0 (en) * 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
US4927571A (en) * 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US6277410B1 (en) 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
US6060518A (en) * 1996-08-16 2000-05-09 Supratek Pharma Inc. Polymer compositions for chemotherapy and methods of treatment using the same
US20030157082A1 (en) * 2002-01-31 2003-08-21 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules
JP2004010479A (ja) * 2002-06-03 2004-01-15 Japan Science & Technology Corp ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法
GB0312309D0 (en) * 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome

Also Published As

Publication number Publication date
EP1991239B1 (en) 2014-09-17
HK1130661A1 (en) 2010-01-08
JP5449784B2 (ja) 2014-03-19
US20070196493A1 (en) 2007-08-23
KR20080110755A (ko) 2008-12-19
KR101074430B1 (ko) 2011-10-17
CA2640997A1 (en) 2007-08-30
CN101389343A (zh) 2009-03-18
EP1991239A1 (en) 2008-11-19
JP2009527505A (ja) 2009-07-30
WO2007095722A1 (en) 2007-08-30
US8148338B2 (en) 2012-04-03
EP1991239A4 (en) 2012-09-19
CN101389343B (zh) 2012-08-22

Similar Documents

Publication Publication Date Title
CA2640997C (en) Doxorubicin formulations for anti-cancer use
TW201909904A (zh) 高濃度調配物
NL2023661B1 (en) Pharmaceutical Eutectic Salt Formulation
AU2019321089A1 (en) Liquid bendamustine pharmaceutical compositions
Gaur et al. Formulation and characterization of fast disintegrating tablet of aceclofenac by using sublimation method
CN111249229A (zh) 一种稳定的法匹拉韦注射液及其制备方法
KR20170091778A (ko) 약제학적 페메트렉시드 액제
RU2557919C1 (ru) Сыпучий прессуемый порошок рапамицина и фармацевтическая композиция на его основе
US20200138840A1 (en) Pharmaceutical composition and tumor immunoactivity promoter
ES2900171T3 (es) Composición inyectable
CN116637095A (zh) 具有增强的稳定性和生物利用度的制剂
Olajide et al. Physicochemical properties of some paediatric and adult products of dihydroartemisinin-piperaquine antimalarial marketed in Nigeria
CN104027307A (zh) 药物组合物及其制备方法
HK1130661B (en) Doxorubicin formulations for anti-cancer use
Kumar et al. Non Aqueous Formulations and Evaluation of Fosaprepitant Liquid Injectable Dosage Form
TWI489985B (zh) 吉西他濱之不含有機溶劑的水性溶液組合物
Lukkad Harish et al. Formulation and Evaluation of Modified Disintegrating Sustained Release Tablets of Diclofenac Sodium
Rao et al. Formulation and Evaluation of Modified Pulsincap Technique for Oral Controlled Release of Glipizide
Bhat et al. Design and characterization of chronopharmaceutical drug delivery of theophylline
Yadav et al. FORMULATION AND EVALUATION OF SUSTAINED RELEASE MATRIX TABLETS OF ATENOLOL
CN119546305A (zh) 泛raf激酶抑制剂的口服液体悬浮液
CN116997323A (zh) 包含利培酮和可生物降解的聚合物的长效可注射制剂
Rao et al. Design and Development of Modified Pulsincap Technique for Oral Controlled Release of Rosiglitazone Maleate
Madhusudhana Formulation and in vitro evaluation of microparticulate carrier for antiviral drug

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250808

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106